Tags

Type your tag names separated by a space and hit enter

VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma.
Cancer. 2008 Jan 15; 112(2):433-42.C

Abstract

BACKGROUND

Tumor angiogenesis is a dynamic process that plays a major role in cancer progression. Vascular endothelial growth factor (VEGF) and its receptors play a pivotal role in angiogenesis. The expression of VEGF and its receptors VEGFR-1 and VEGFR-2 in renal cell carcinoma (RCC) was investigated in the perspective of anti-VEGF treatments.

METHODS

Total VEGF protein levels were quantified by enzyme-linked immunosorbent assay (ELISA) in tumor tissue samples from surgical specimens of 65 patients with clear cell RCC. At the cellular level the VEGF isoforms VEGFR-1 and VEGFR-2 mRNA were quantified by real-time quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) in laser-microdissected tumoral epithelial as stromal cells and in corresponding normal tissue compartments. Colocalization of VEGF and VEGFR-1 proteins was studied by triple immunofluorescent labeling.

RESULTS

Protein VEGF in cytosolic extracts was significantly higher in tumoral than in nontumoral tissue (P< .0001). Event-free survival was significantly longer for patients with cytosolic VEGF lower than the cutoff (75th percentile of VEGF protein levels, P= .02). In laser-microdissected epithelial cells, VEGF(121) and VEGFR-1 mRNA expressions were higher in RCC than in corresponding nontumoral kidney (P= .007 and P= .002, respectively); they were also higher in stromal cells of RCC compared with nontumoral kidney (P= .02 and P= .003, respectively). There was no differential VEGFR-2 expression in epithelial or in stromal cells of tumoral or nontumoral kidney. By immunofluorescent labeling VEGF and VEGFR-1 colocalized on RCC tumor epithelial and stromal cells.

CONCLUSIONS

Combined laser microdissection and quantitative RT-PCR, as triple immunofluorescent labeling, underlined the preferential expression of the most soluble VEGF isoform, VEGF(121), and its receptor VEGFR-1, but not VEGFR-2, in epithelial and stromal cells of RCC.

Authors+Show Affiliations

Laboratoire de Pathologie and U728, INSERM, Université Paris 7, Hôpital Saint-Louis, AP-HP, and Institut Universitaire d'Hématologie, Paris, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18041056

Citation

Rivet, Jacqueline, et al. "VEGF and VEGFR-1 Are Coexpressed By Epithelial and Stromal Cells of Renal Cell Carcinoma." Cancer, vol. 112, no. 2, 2008, pp. 433-42.
Rivet J, Mourah S, Murata H, et al. VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma. Cancer. 2008;112(2):433-42.
Rivet, J., Mourah, S., Murata, H., Mounier, N., Pisonero, H., Mongiat-Artus, P., Teillac, P., Calvo, F., Janin, A., & Dosquet, C. (2008). VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma. Cancer, 112(2), 433-42.
Rivet J, et al. VEGF and VEGFR-1 Are Coexpressed By Epithelial and Stromal Cells of Renal Cell Carcinoma. Cancer. 2008 Jan 15;112(2):433-42. PubMed PMID: 18041056.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma. AU - Rivet,Jacqueline, AU - Mourah,Samia, AU - Murata,Hideyuki, AU - Mounier,Nicolas, AU - Pisonero,Helena, AU - Mongiat-Artus,Pierre, AU - Teillac,Pierre, AU - Calvo,Fabien, AU - Janin,Anne, AU - Dosquet,Christine, PY - 2007/11/28/pubmed PY - 2008/2/22/medline PY - 2007/11/28/entrez SP - 433 EP - 42 JF - Cancer JO - Cancer VL - 112 IS - 2 N2 - BACKGROUND: Tumor angiogenesis is a dynamic process that plays a major role in cancer progression. Vascular endothelial growth factor (VEGF) and its receptors play a pivotal role in angiogenesis. The expression of VEGF and its receptors VEGFR-1 and VEGFR-2 in renal cell carcinoma (RCC) was investigated in the perspective of anti-VEGF treatments. METHODS: Total VEGF protein levels were quantified by enzyme-linked immunosorbent assay (ELISA) in tumor tissue samples from surgical specimens of 65 patients with clear cell RCC. At the cellular level the VEGF isoforms VEGFR-1 and VEGFR-2 mRNA were quantified by real-time quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) in laser-microdissected tumoral epithelial as stromal cells and in corresponding normal tissue compartments. Colocalization of VEGF and VEGFR-1 proteins was studied by triple immunofluorescent labeling. RESULTS: Protein VEGF in cytosolic extracts was significantly higher in tumoral than in nontumoral tissue (P< .0001). Event-free survival was significantly longer for patients with cytosolic VEGF lower than the cutoff (75th percentile of VEGF protein levels, P= .02). In laser-microdissected epithelial cells, VEGF(121) and VEGFR-1 mRNA expressions were higher in RCC than in corresponding nontumoral kidney (P= .007 and P= .002, respectively); they were also higher in stromal cells of RCC compared with nontumoral kidney (P= .02 and P= .003, respectively). There was no differential VEGFR-2 expression in epithelial or in stromal cells of tumoral or nontumoral kidney. By immunofluorescent labeling VEGF and VEGFR-1 colocalized on RCC tumor epithelial and stromal cells. CONCLUSIONS: Combined laser microdissection and quantitative RT-PCR, as triple immunofluorescent labeling, underlined the preferential expression of the most soluble VEGF isoform, VEGF(121), and its receptor VEGFR-1, but not VEGFR-2, in epithelial and stromal cells of RCC. SN - 0008-543X UR - https://www.unboundmedicine.com/medline/citation/18041056/VEGF_and_VEGFR_1_are_coexpressed_by_epithelial_and_stromal_cells_of_renal_cell_carcinoma_ L2 - https://doi.org/10.1002/cncr.23186 DB - PRIME DP - Unbound Medicine ER -